TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04027439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part B: RPL554
Description: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.
Study: NCT01693289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin plus letrozole

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian drilling
Study: NCT02261402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medisinstart
Description: Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
Study: NCT00604357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD 25 mAb, Sirolimus, MMF
Description: Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter).
Study: NCT06267495

Intervention type: PROCEDURE
Intervention: Epithelium-on corneal cross-linking (epi-on CXL)
Description: In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
Study: NCT00951496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03814525

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
Study: NCT04645836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New management mode
Description: New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use
Study: NCT03055559

Intervention type: DIETARY_SUPPLEMENT
Intervention: Globifer Forte
Study: NCT04564365

Intervention type: DRUG
Intervention: beta-blocker
Description: To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
Study: NCT02550951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography
Study: NCT02712060

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT04591223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competency-based physical training (CbM)
Description: The intervention to be added to online social work treatment as usual (OSW) is a well-designed, one-on-one structural physical workout module which will be offered by a licensed senior physical trainer in public sports ground or gymnasium. The aim is to strengthen participants' sense of competence, improve their physical fitness, self-confidence and self-image through an outcome-driven Circuit training. One of the chief advantages of Circuit training is its adaptability. Circuit training can be performed with gym equipment and/or bodyweight exercises which is deemed to be suitable for beginner and easy to practice at home on oneself. Participants can continue to replicate the exercise with or without any equipment. The program will be delivered in six one-hour sessions, including face-to-face and online mode, over one month.
Study: NCT00721630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, lapatinib
Description: Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
Study: NCT02123082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz single Lumen Ureteroscope
Description: Single lumen, flexible scope for ureteroscopies

Intervention type: DEVICE
Group type: OTHER
Intervention: Storz single Lumen Ureteroscope
Description: Single lumen, flexible scope for ureteroscopies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Lumen Ureteroscope
Description: Dual lumen, flexible scope for ureteroscopies

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual Lumen Ureteroscope
Description: Dual lumen, flexible scope for ureteroscopies
Study: NCT01046786

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 30 mg/kg methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 30 mg/kg methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: oral lithium, titrated to maintain 0.6-1.0 mM serum level
Study: NCT00492024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin - 400 mg once a day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 380 mg Microcrystalline Cellulose
Study: NCT01399567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm
Description: The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
Study: NCT01085201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given as an infusion
Study: NCT02531750

Intervention type: OTHER
Intervention: Immobilization due to an Achilles tendon rupture
Study: NCT00201409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by slow intravenous infusion once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
Study: NCT03309995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lozenges
Description: The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: Placebo lozenges
Study: NCT03173326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
Study: NCT00902317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoplasty (PolarCath peripheral balloon catheter)
Description: Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Angioplasty (Spectranetics)
Description: The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SilverHawk Atherectomy
Description: Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viabahn Endograft
Description: The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty/Stent (Guidant Absolute stent)
Description: A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
Study: NCT01802450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT04504305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeuropAWAY
Description: 2 capsules thrice daily to be taken half an hour prior to meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcystalline cellulose
Description: 2 capsules thrice daily to be taken half an hour prior to meal.
Study: NCT00790335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Description: Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
Study: NCT00933348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPAL A
Description: OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
Study: NCT01342900

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: connected to the InSpectra Monitor
Study: NCT03850925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: 4 consecutive sessions of laser therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: 4 consecutive sessions of laser therapy
Study: NCT03509805

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography
Study: NCT02213510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip Surgical Skin Closure Device
Description: The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Suture Closure
Description: The surgeon will perform standard suture closure for the skin layer following CIED procedure.
Study: NCT02935621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study: NCT00554190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdvaCoat sinus gel
Description: A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merogel Injectable
Description: Bioresorbable hyaluronic acid product
Study: NCT02902367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outdoor walking and strength exercise
Description: Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
Study: NCT01177475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples , feces samples
Description: After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood samples, feces samples
Description: After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
Study: NCT02359994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerClot Polysaccharide Hemostatic System
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerClot Polysaccharide Hemostatic System
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerClot Polysaccharide Hemostatic System
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista AH
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista AH
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista AH
Description: During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
Study: NCT04639804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg capsule
Study: NCT04562155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study drug BAY1817080 will be administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study drug BAY1817080 will be administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study drug BAY1817080 will be administered orally as tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for BAY1817080 will be administered orally as tablet.
Study: NCT03893097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: 40 mg/kg at baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate + Mefloquine
Description: 4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12